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Summary Over the last decade, bacteriophages (bacterial viruses) have emerged as the major
alternative to antibiotics in the treatment of antibiotic-resistant infections. While a considerable
body of evidence has accumulated for the efficacy and safety of phage therapy in immunocom-
petent patients, data remain relatively scarce regarding its use in the immunocompromised host.
To our knowledge, the present article is the first to summarize all findings, of both experimental
and clinical studies, that may be relevant to the employment of phage therapy in immunocom-
promised patients. The available data suggest that bacteriophages could also be an efficacious
and safe therapeutic modality in such patients.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Recent years have witnessed a substantial increase in the
prevalence of antibiotic resistance in many clinically rele-
vant bacteria, especially staphylococci and enterococci, as
well as Pseudomonas aeruginosa, Acinetobacter baumanii,
and extended-spectrum b-lactamase (ESBL)-producing
Enterobacteriaceae.1 At the same time, the pace of devel-
opment of new antibiotics has been inadequate, resulting in a
shortage of novel classes of antibacterial agents with which
to eliminate multidrug-resistant pathogens.2,3 This dramatic* Corresponding author. Tel.: +48 22 502 12 62;
fax: +48 22 502 21 59.
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doi:10.1016/j.ijid.2008.01.006situation has created an urgent need for the development of
alternative anti-infectives.4
Currently, some of the most promising new antibacterial
agents are lytic bacteriophages (phages), i.e., viruses that
infect and kill solely bacterial cells.5,6 While no relevant
clinical trials meeting current standards of clinical research
have been conducted as yet, a growing body of data,
obtained from both preclinical studies and numerous
uncontrolled clinical trials, show that phages may be an
effective and safe means of killing antibiotic-resistant
bacteria. For example, two recent studies revealed a high
efficacy of specific bacteriophages in murine models of
infections with methicillin-resistant Staphylococcus aureus
(MRSA)7,8 and imipenem-resistant P. aeruginosa,9 both of
which belong to the group of most problematic bacterial
pathogens.Published by Elsevier Ltd. All rights reserved.
Phage therapy in the immunocompromised host 467In humans, phages seem to be efficacious in a wide range
of infections, both local and systemic, as evidenced by
positive results of many clinical trials, largely from Eastern
European centers.10—12 However, the vast majority of these
studies have been performed on immunocompetent
patients,10,11 and data on the therapeutic use of bacterio-
phages in the immunocompromised host are scarce. Never-
theless, several important conclusions on the efficacy and
safety of phage therapy in patients with impaired immunity
may be drawn on the basis of results of other studies, for
instance those regarding phage treatment of bacterial infec-
tions in immunocompetent hosts or the use of phages for the
diagnosing and monitoring of patients with different immu-
nodeficiencies.13,14 This topic has great importance to clin-
ical medicine because bacterial infections, including those
caused by antibiotic-resistant strains, are one of the most
significant causes of morbidity and mortality in immunocom-
promised patients, including allograft recipients,15—20 cancer
patients,21,22 individuals with primary immunodeficiencies,23
and AIDS patients.24,25
Phage therapy
Phage therapy relies on the use of lytic phages, i.e., viruses
that infect and kill solely bacterial cells, for the treatment of
bacterial infections, especially those caused by antibiotic-
resistant bacteria (for reviews on the history, current status,
and perspectives of phage therapy, see references 5, 6, and
10—12). The major characteristics of phages as potential
antibacterial agents include bactericidal activity against
Gram-positive7 and Gram-negative26 bacteria both in vitro
and in vivo, their novel mechanism of action,27 the capacity
for killing antibiotic-resistant bacteria,7—9,28,29 a narrow
antibacterial range, usually restricted to some strains within
a single bacterial species,29 and their lack of toxic effects on
mammalian cells.30,31
The vast majority of clinical trials involving the use of
bacteriophages have been conducted in Eastern Europe,
especially in Poland, Georgia, and Russia. Basically, the
results of most of these studies seem encouraging, with
phages being shown very effective in a wide range of both
local and systemic infections caused by different species of
antibiotic-resistant bacteria.10—12 Equally important, it has
been a consistent finding that no serious side effects occur in
patients even following repeated administration of
phages.10,32 However, practically none of the hitherto con-
ducted studies meet the current stringent criteria for clinical
research, so their results must ultimately be verified by
randomized controlled trials.
The last decade has brought several substantial develop-
ments in phage therapy, which is currently arousing ever-
greater interest in Western medicine as an alternative to
antibiotics in the treatment of infections caused by multi-
drug-resistant bacteria.6,33 First, major advances in phage
biology, genomics, and biotechnology have allowed the
development of purified preparations of well-characterized
and effective phages.30,31 Second, several high-quality
experimental studies have confirmed the high efficacy of
phage therapy in infections caused by antibiotic-resistant
strains of different clinically relevant bacterial species,
including MRSA,7,8 vancomycin-resistant Enterococcus fae-cium (VRE),29 ESBL-producing Escherichia coli,28 as well as
imipenem-resistant P. aeruginosa.9 Third, in 2005 the Center
for Phage Therapy was opened in Wrocław, Poland, where for
the first time in the European Union, patients with a wide
range of antibiotic-resistant bacterial infections can be offi-
cially treated with bacteriophages (www.iitd.pan.wroc.pl/
phages/phages.html).34 Furthermore, the first placebo-con-
trolled safety test involving T4 phage was recently carried
out at the Nestle Research Center, Switzerland, preliminarily
confirming the lack of toxicity of bacteriophage preparation
following oral administration.35 Finally, in 2006 the US Food
and Drug Administration (FDA) approved the use of the first
bacteriophage preparation containing six different phages
specific against Listeria monocytogenes as a food additive
(www.cfsan.fda.gov/dms/opabacqa.html).
Taken together, these data clearly show that bacterio-
phages are gradually becoming reliable antibacterial agents
that have good prospects for wider clinical use in Western
medicine. Of particular importance is a recent report indicat-
ing that successful phage therapy of staphylococcal infections,
including those caused by MRSA, is much less expensive than
antibiotic treatment. This implies that wider phage applica-
tion could also be beneficial for the economy of healthcare, a
factor that must be considered in every country.36
Phage therapy in the immunocompromised
host
Therapeutic efficacy
One of the main questions that need to be addressed in the
context of the use of bacteriophages in the treatment of
bacterial infections in immunocompromised patients is that
regarding the general mode of antibacterial activity of
phages. Essentially, the in vivo therapeutic effect of a phage
preparation could be mediated by either of two major
mechanisms. The first relies on direct killing of bacterial
cells by bacteriophage virions over the course of the lytic
cycle, whereas the other depends on inducing an antibacter-
ial immune response by either the phage particles them-
selves or other components of the phage preparation,
especially some constituents of bacterial cells. Such consti-
tuents (e.g., lipopolysaccharide; LPS) are found in large
quantities in crude phage lysates and may remain in small
amounts even in purified preparations owing to the imper-
fection of the current purification methods.31,37 Indeed,
some phage preparations, especially lysates, have been
found to exert immunostimulatory activity, an example being
staphage lysate (SPL).14 This problem is of great importance
in phage therapy because an immune response-mediated
antibacterial activity may be substantially suppressed in
immunocompromised patients.38 Thus, were the in vivo ther-
apeutic effect of bacteriophages at least partly mediated by
the immune system, the therapeutic effectiveness of phages
could be limited in immunocompromised patients.
However, several interesting experiments performed on
immunocompetent mice strongly suggest that it is direct
killing of bacteria by phage virions that is the major mechan-
ism mediating the in vivo therapeutic effect of phage pre-
parations, the induction of an antibacterial immune response
playing practically no role in this regard. First, a correlation
468 J. Borysowski, A. Go´rskiwas found between phage antibacterial activities in vitro and
their therapeutic effects in vivo. This means that only phages
capable of lysing bacterial cells in vitro could cure infection
in mice, while those inactive in vitro (but potentially capable
of inducing an antibacterial immune response) were also
ineffective in vivo. Interestingly, phages acting more
potently in vitro were found to be more efficient in vivo.26
Moreover, in a murine model of S. aureus bacteremia it was
shown that a mechanical lysate of staphylococci, containing
all the components of bacterial cells that may be present in a
phage preparation, is not capable of curing infection; cure
was achieved only by using a preparation containing func-
tional bacteriophage virions.7
In another experiment the possibility was ruled out that
phage particles themselves induce an antibacterial immune
response. This was shown by comparing the therapeutic
effect of staphylococcal ØMR11 phage in a murine model
of bacteremia caused by a ØMR11-sensitive S. aureus strain,
termed SA37, with that induced by ØMR11 lysogen of SA37.
This lysogen is identical to the parental SA37 strain except for
its insusceptibility to ØMR11 phage. It was shown that the
phage preparation could cure only infection caused by the
SA37 strain, being ineffective in bacteremia induced by the
lysogenized strain (if the therapeutic effect were mediated
by a phage virion-induced immune response, the phage pre-
paration would have been effective in both cases).7 Similar
results were obtained in three separate studies in which the
therapeutic effects of preparations containing nonfunctional
(heat-inactivated) phages were compared with those of
preparations based on functional virions.9,28,29 Predictably,
only the latter were effective, whereas the activities of the
former were drastically diminished.
Taken together, the above data clearly show that the only
significant mechanism mediating the in vivo therapeutic
effects of phage preparations is direct killing of bacterial
cells by phage virions, their potential immunostimulatory
activity being negligible. This is a very important conclusion
because it implies that bacteriophages will essentially be
able to eliminate bacteria also in the immunocompromised
host. However, their therapeutic efficacy might be limited to
some extent by the development of bacterial resistance. It is
known that bacteriophage-resistant bacterial mutants can be
isolated following exposure of bacteria to phages both in
vitro and in vivo.26 In immunocompetent individuals, phage-
resistant bacteria that remain viable after the elimination of
phage-sensitive bacterial cells by bacteriophages can be
cleared by the immune system, especially when treating
acute infections.39 In the immunocompromised patient, how-
ever, these bacteria might not be efficiently eliminated by
cells of the immune system due to their impaired function,
which could decrease the overall efficacy of the treatment.
On the other hand, the state of immunosuppression could be
advantageous with respect to the pharmacokinetics of
phages, as it would slow down the clearance of virions from
the circulation. While earlier studies stressed the importance
of the reticulo-endothelial system of the liver and spleen in
removing phage particles from the blood,40 newer experi-
ments have revealed that B cells are also very important in
this regard.41 This was shown by comparing the half-lives of
T7 phage in mice with different kinds of immunodeficiency.
Only in the B cell-deficient mice was the T7 half-life sub-
stantially prolonged, while in T cell-deficient, NK cell-depleted, and macrophage-depleted mice the kinetics of
phage clearance was comparable to that found in wild-type
mice.41 Likewise, Ø X174 phage, used for the evaluation of
humoral immunity in immunocompromised patients, is
cleared from the circulation more slowly in the case of severe
immunodeficiency (see below, ‘safety issues’). Thus, at least
in some individuals with impaired humoral immunity, the
half-life of phages administered for therapeutic purposes
is likely to be prolonged, thereby increasing the efficiency
of the treatment.
To the best of our knowledge, no preclinical study has been
reportedas yet toevaluate theefficacyofphage therapy in the
immunocompromised host. However, our preliminary results
show that a P. aeruginosa-specific bacteriophage is effective in
a model of imipenem-resistant P. aeruginosa bacteremia in
cyclosporine-immunosuppressed mice (Borysowski J., unpub-
lished results). Further experiments are underway to evaluate
the effectiveness of phages in the treatment of antibiotic-
resistant infections in othermurinemodels of immunosuppres-
sion (Zimecki M., unpublished results).
As mentioned above, clinical data are very scanty regard-
ing the use of phage therapy in immunocompromised
patients. In fact, to our knowledge only four clinical trials
have been conducted to evaluate the therapeutic efficacy of
bacteriophages in such patients. The first was performed on
131 cancer patients with postoperative wound infections
caused by different Gram-positive and Gram-negative bac-
teria. Sixty-five of these received topical phage treatment (in
some cases along with antibiotics), whereas 66 subjects were
administered antibiotics only. Overall, phage therapy was
effective in 81.5% of the patients, while in the subjects who
received antibiotics only, the cure rate was 60.6%.42 The
second study involved 59 leukemic patients with dysentery
who were administered phages, bifidobacteria, phages along
with bifidobacteria, or antibiotics not absorbable in the gut.
The highest cure rate was obtained in subjects treated with a
combination of phages and bifidobacteria.43 In the third
study, 20 cancer patients (aged 1—66 years, 17 with solid
tumors and three with hematological malignancies) were
enrolled with a range of infections, including postoperative
infections, septicemia, skin infections, pneumonia, decubi-
tus, post-X infections, and meningitis. Etiological agents of
these infections included antibiotic-resistant strains of S.
aureus, P. aeruginosa, Klebsiella pneumoniae, Klebsiella
oxytoca, and E. coli. Specific bacteriophages were adminis-
tered orally three times daily for 2—9 weeks (median: 32
days). Eight patients were also administered phages topi-
cally. While the authors reported that positive results of the
treatment were achieved in all subjects, their data should be
evaluated with caution owing to the significant methodolo-
gical shortcomings of the study, especially a failure to include
a control group.44 The fourth study was performed on 15
patients with chronic urinary tract infections, of whom three
were renal allograft recipients. In the allograft recipients the
infections were caused by P. aeruginosa (two subjects) and K.
pneumoniae (one subject). Phages were administered 3—4
times daily for 3—11 months (median: 5.4 months), at first
along with antibiotics. In one patient, remission of clinical
symptoms and urine sterilization were achieved, which
remained over the one-year observation period. In the other
two patients, however, recurrence of infection occurred,
which required the reintroduction of antibiotic therapy.45
Phage therapy in the immunocompromised host 469Safety issues
Concern over the safety of phage therapy in immunocom-
promised patients may arise from the viral nature of bacter-
iophages combined with the data on the detrimental effects
of some viruses on the immunocompromised host. For
instance, it is known that immunocompromised patients
are at higher risk of developing many serious viral infections,
including those caused by cytomegalovirus (CMV),46 Epstein—
Barr virus (EBV),47 or adenoviruses.48 Furthermore, vaccines
containing live viruses, relatively innocuous for immunocom-
petent individuals, can cause disseminated infections follow-
ing administration to immunocompromised patients.38
Moreover, some viruses, especially BK virus (BKV) and CMV,
may contribute to allograft rejection. The former is the
major etiological agent of polyomavirus-associated nephro-
pathy (PVAN), which results in graft loss in over 50% of
cases,49 while the latter may be involved in renal, heart,
lung, and liver allograft rejection.50,51 Finally, EBV is the
major factor implicated in the pathogenesis of a heteroge-
neous group of lymphomas collectively referred to as post-
transplant lymphoproliferative disorder (PTLD), being the
second most common malignancy in adult solid-organ reci-
pients.52
In view of the viral nature of bacteriophages, these data
could be interpreted as suggesting that administration of
phages could also pose some risk to immunocompromised
patients. However, a considerable body of evidence shows
that phages, unlike pathogenic viruses, are innocuous for
individuals with impaired immunity, including allograft reci-
pients. First, in the above-mentioned clinical studies, no
serious side effects were found, even in spite of the phage
preparations being administered three or four times daily for
several weeks.44,45 Furthermore, in allograft recipients the
treatment did not adversely affect graft function, as evi-
denced by the lack of any abnormalities in standard labora-
tory tests. In fact, in two of the three subjects, serum
creatinine levels dropped from 260 mmol/l to 210 mmol/l
following cure of infection.45 Finally, there are some data
indicating that at least some bacteriophages in a well-pur-
ified form can in fact exert anticancer activity in mice.53—55
Important data implying a lack of deleterious effects of
bacteriophages on the immunocompromised host also come
from studies on the diagnostic use of ØX174 coliphage, which
is currently one of the standard antigens for the evaluation of
humoral immunity in clinical immunology.13,14 For over 30
years it has been administered intravenously to many indi-
viduals with both primary and secondary immunodeficien-
cies, including adenosine deaminase deficiency, X-linked
agammaglobulinemia, X-linked hyper-IgM syndrome, major
histocompatibility complex class II deficiency, Wiskott—
Aldrich syndrome, AIDS, and the immunodeficiency state
after bone marrow transplantation. In none of these patients
have any side effects been found following phage injection,
suggestive of a lack of toxic effects of phage particles on the
immunocompromised host.13,14
Immunomodulatory activity of bacteriophages
Another problem that needs to be taken into consideration
before employing phage therapy in immunocompromised
patients is that of the potential immunomodulatory activityof bacteriophages. Although knowledge about the effects of
phages on the immune system is quite fragmentary and some
findings may be considered preliminary, it seems that lysates
(unpurified phage preparations) may exert immunostimula-
tory activity, whereas at least some bacteriophages in a well-
purified form (e.g., T4) can inhibit some basic functions of
cells of the immune system.14,56,57
We will focus here on purified preparations because these
are more likely to be approved formally for clinical use. If the
immunosuppressive activity of purified phage preparations
was confirmed for other bacteriophages, this could have
important clinical implications. On the one hand, immuno-
suppressive activity of purified bacteriophages might be
considered an argument for the safety of phage therapy,
especially when treating allograft recipients. In these
patients, a nonspecific immunostimulatory activity of phages
would be disadvantageous as it could accelerate allograft
rejection. On the other hand, too high a level of immuno-
suppression, resulting from simultaneous activities of immu-
nosuppressive drugs and phages, could increase the risk of
other infections. Obviously, cancer patients and individuals
with other immunodeficiencies would also be at higher risk of
infections following administration of phages. However, bac-
teriophages are usually administered for a relatively short
period of time and therefore their immunosuppressive activ-
ity might not substantially increase the incidence of treat-
ment-induced infections. Besides, phages are most likely to
be used in infections caused by multidrug-resistant bacteria,
where they may prove to be the only therapeutic modality
enabling one to cure the infection. Finally, in some clinical
situations in which additional phage-mediated immunosup-
pressive activity would be disadvantageous, one could
employ phage lysates rather than purified preparations.
Thesemight be used, for instance, in individuals with primary
immunodeficiencies, for whom the immunostimulatory activ-
ity of lysates could be beneficial.
Conclusions
At the current stage of research, phage therapy appears to be
a safe and effective means of treating antibiotic-resistant
infections, especially in immunocompetent patients. On the
other hand, data are scarce regarding the efficacy of phage
therapy and the effects of bacteriophages on the immuno-
compromised host. Nonetheless, when combined with the
results of other phage studies, these data suggest that
bacteriophages may also be efficacious and safe in individuals
with impaired immunity.
In our opinion, three major lines of research will be
essential for the evaluation of the usefulness of phage ther-
apy for immunosuppressed patients. First, the efficacy of
phage therapy should be evaluated in experimental models of
immunosuppression as well as in controlled clinical trials
involving immunocompromised patients. Second, the poten-
tial effects of bacteriophages on the immunocompromised
host need to be investigated in detail. This line of research
gains special importance in light of data on the deleterious
effects of some viruses on the immunocompromised host. In
allograft recipients, of particular importance will be a
detailed analysis of the influence of phages on different
aspects of the graft function. Finally, research into the
immunomodulatory activity of phages should be continued,
470 J. Borysowski, A. Go´rskias this activity is one of the major aspects of the safety of
phage therapy in immunosuppressed patients. For instance,
nonspecific immunomodulatory activity of phage prepara-
tions would be disadvantageous for allograft recipients, as it
could accelerate allograft rejection. Thus, it appears that
each phage preparation should be investigated also in terms
of its potential immunomodulatory activity before being
administered to immunosuppressed patients.
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